Delano Ladd - HealthEquity President
HQY Stock | USD 79.85 0.02 0.03% |
President
Mr. Delano W. Ladd is Executive Vice President, General Counsel and Corporationrationrate Secretary of the Company. Mr. Ladd has served as our Executive Vice President, General Counsel and Corporationrationrate Secretary since September 2016, having previously served as our Deputy General Counsel from April 2016 to September 2016. Prior to joining HealthEquity, Mr. Ladd worked as an attorney in the Corporationrationrate and Financial Services practice group in the New York office of Willkie Farr Gallagher LLP since 2016.
Age | 43 |
Tenure | 8 years |
Address | 15 West Scenic Pointe Drive, Draper, UT, United States, 84020 |
Phone | 801 727 1000 |
Web | https://www.healthequity.com |
Latest Insider Transactions
Ladd holds a B.A. from the University of Colorado and a J.D. from St. John University School of Law.Delano Ladd Latest Insider Activity
Tracking and analyzing the buying and selling activities of Delano Ladd against HealthEquity stock is an integral part of due diligence when investing in HealthEquity. Delano Ladd insider activity provides valuable insight into whether HealthEquity is net buyers or sellers over its current business cycle. Note, HealthEquity insiders must abide by specific rules, including filing SEC forms every time they buy or sell HealthEquity'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Delano Ladd over a week ago Disposition of 1684 shares by Delano Ladd of HealthEquity at 80.5956 subject to Rule 16b-3 | ||
Delano Ladd over two weeks ago Acquisition by Delano Ladd of 11711 shares of HealthEquity subject to Rule 16b-3 |
HealthEquity Management Efficiency
The company has Return on Asset of 0.0256 % which means that on every $100 spent on assets, it made $0.0256 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0284 %, implying that it generated $0.0284 on every 100 dollars invested. HealthEquity's management efficiency ratios could be used to measure how well HealthEquity manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.07 in 2024, whereas Return On Capital Employed is likely to drop 0.04 in 2024. At this time, HealthEquity's Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 51 M in 2024, whereas Other Assets are likely to drop 0.95 in 2024.Similar Executives
Showing other executives | PRESIDENT Age | ||
Nicholas Meeks | Streamline Health Solutions | 32 | |
Mollie Condra | HealthStream | N/A | |
Brett Howell | Simulations Plus | 40 | |
Robert Creviston | Agiliti | 57 | |
Thomas Gibson | Streamline Health Solutions | 60 | |
William Garvis | Streamline Health Solutions | 50 | |
Leif Pedersen | Certara | 59 | |
Jeffrey Cunningham | HealthStream | 57 | |
Edward Pearson | HealthStream | 61 | |
Matthew Mccabe | Agiliti | 43 | |
Patrick PharmD | Certara | 53 | |
Michael Collier | HealthStream | 48 | |
Nicholas McGrane | Evolent Health | 49 | |
Bettyann Bird | Agiliti | 63 | |
Trisha Coady | HealthStream | 48 | |
Shaun Priest | Streamline Health Solutions | 46 | |
Jonathan Maack | Definitive Healthcare Corp | 45 | |
Thomas Schultz | HealthStream | 49 | |
Robert Aspbury | Certara | 52 | |
Jeffery Doster | HealthStream | 51 | |
James Pekarek | Agiliti | 55 |
Management Performance
Return On Equity | 0.0284 | ||||
Return On Asset | 0.0256 |
HealthEquity Leadership Team
Elected by the shareholders, the HealthEquity's board of directors comprises two types of representatives: HealthEquity inside directors who are chosen from within the company, and outside directors, selected externally and held independent of HealthEquity. The board's role is to monitor HealthEquity's management team and ensure that shareholders' interests are well served. HealthEquity's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, HealthEquity's outside directors are responsible for providing unbiased perspectives on the board's policies.
Matthew Sydney, Executive VP of Sales and Marketing | ||
Frode Jensen, Executive Vice President - General council and secretery | ||
Robert Selander, Non-Executive Chairman of the Board | ||
Evelyn Dilsaver, Independent Director | ||
Edward Bloomberg, COO, Executive Vice President | ||
Adrian Dillon, Director | ||
William Otten, Executive Vice President of Sales | ||
Larry Trittschuh, Executive Vice President Chief Security Officer | ||
Jon Kessler, CEO and President and Director | ||
Stephen Neeleman, Vice Chairman of the Board, Founder | ||
Delano Ladd, Executive Vice President General Counsel and Corporate Secretary | ||
Jon Soldan, Executive VP of Operations | ||
Debra McCowan, Director | ||
Frank Corvino, Independent Director | ||
Manu Rana, Independent Director | ||
Gary Robinson, Executive Vice President Chief Marketing Officer | ||
Elimelech Rosner, Executive CTO | ||
Tia Padia, Executive Officer | ||
Richard Putnam, IR Contact Officer | ||
James Lucania, CFO VP | ||
Ian Sacks, Independent Director | ||
Angelique Hill, Executive Vice President - Operations | ||
Michael Leavitt, Independent Director | ||
Darcy Mott, CFO, Executive VP and Treasurer | ||
Gayle Wellborn, Director | ||
Brad Bennion, Senior Development | ||
Tyson Murdock, Ex CFO | ||
Jonathan Soldan, Executive Vice President - Operations | ||
Steve Lindsay, Executive Management | ||
Frank Medici, Independent Director | ||
Ashley Dreier, Executive Vice President CTO and CIO |
HealthEquity Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is HealthEquity a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0284 | ||||
Return On Asset | 0.0256 | ||||
Profit Margin | 0.06 % | ||||
Operating Margin | 0.16 % | ||||
Current Valuation | 7.41 B | ||||
Shares Outstanding | 86.16 M | ||||
Shares Owned By Insiders | 2.22 % | ||||
Shares Owned By Institutions | 97.78 % | ||||
Number Of Shares Shorted | 2.98 M | ||||
Price To Earning | 525.29 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HealthEquity. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index. For more information on how to buy HealthEquity Stock please use our How to Invest in HealthEquity guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for HealthEquity Stock analysis
When running HealthEquity's price analysis, check to measure HealthEquity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HealthEquity is operating at the current time. Most of HealthEquity's value examination focuses on studying past and present price action to predict the probability of HealthEquity's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HealthEquity's price. Additionally, you may evaluate how the addition of HealthEquity to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
Is HealthEquity's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HealthEquity. If investors know HealthEquity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about HealthEquity listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.96) | Earnings Share 0.64 | Revenue Per Share 11.682 | Quarterly Revenue Growth 0.122 | Return On Assets 0.0256 |
The market value of HealthEquity is measured differently than its book value, which is the value of HealthEquity that is recorded on the company's balance sheet. Investors also form their own opinion of HealthEquity's value that differs from its market value or its book value, called intrinsic value, which is HealthEquity's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because HealthEquity's market value can be influenced by many factors that don't directly affect HealthEquity's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between HealthEquity's value and its price as these two are different measures arrived at by different means. Investors typically determine if HealthEquity is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HealthEquity's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.